Mansfield Bio-Incubator Welcomes PurCell Bio as a New Member

MANSFIELD, MA, April 18, 2024 - We are thrilled to announce that PurCell Bio, Inc. has officially become one of the esteemed biotechnology tenants at Mansfield Bio-Incubator.

Dr. Elizabeth Corbin, PurCell Bio’s CEO, conveyed her excitement, affirming that Mansfield provides the ideal setting for PurCell's groundbreaking environmentally friendly, chemically-defined, and animal origin-free Cell Culture Media Systems, positioning us at the forefront of biotechnology. “Mansfield Bio-Incubator is ideally located to serve the needs of PurCell Bio as we introduce our products to the vitally important biotech hub located in the Boston area. Additionally, the Mansfield management has developed a very flexible format for memberships that grow with the business, and actively supports and promotes its members beyond space and equipment needs to include exposure to investors, workshops on opportunities as they emerge, and cooperation between member companies. They have provided us with a home in the center of the biotech universe, and local knowledge of that amazing landscape and its potential in advancing PurCell Bio’s tools and the advances that they can support to come to the clinic, to the manufacturing bench, and even to the table! "

Henry Lisoukov, PurCell Bio’s Business Development Director, shared his thoughts on this significant milestone: "PurCell Bio was eager to expand its domestic presence on the East Coast of the USA. With Massachusetts being a global Life Science Hub, Mansfield Bio-Incubator emerged as the perfect choice for our future endeavors. Its strategic location offers easy access to key accounts in Cambridge, Boston, Worcester, and Providence. Additionally, proximity to major highways such as Interstate 95, Highways 93 & 495, and the Mass Pike allows seamless travel to various parts of Massachusetts and neighboring states. We are excited to extend our operations in this vibrant state, where our serum-free and animal-origin free cell culture systems can revolutionize drug discovery and research & development projects across diverse companies and organizations."

About PurCell Bio, Inc.

PurCell Bio is a dynamic startup specializing in revolutionary products designed to replace Fetal Bovine Serum (FBS) in various cell culture applications. We take pride in offering environmentally friendly, chemically-defined, and animal origin-free Cell Culture Media Systems that surpass the performance of FBS. Our products find applications in Stem Cells Therapy, Regenerative Medicine, Cell Therapy, Gene Therapy, Tissue Engineering, 3D & 4D Bioprinting, Stem Cells Reprogramming, Organoids & Spheroids, Lab-Grown Meat, and many other fields.

Connect with Us!

PurCell Bio, Inc. - Bozeman, MT

770 Osterman Drive, Unit B,

Bozeman, MT 59715.

Website: www.purcell-bio.com

LinkedIn: https://www.linkedin.com/company/purcell-bio/

Local MT Contact:

Kris Veltkamp

CFO

kveltkamp@purcell-bio.com

Business: (406) 206-3004

Cell: (406) 580-2749

Email: kveltkamp@purcell-bio.com

PurCell Bio, Inc. - Mansfield, MA

241 Francis Avenue,

Mansfield, MA 02048

Local MA Contact:

Henry Lisoukov, MBA

Director of Business Development

Business: (406) 206-3004

Cell: (508) 840-9269

Email: hlisoukov@purcell-bio.com

Let's embark on this exciting journey together!

Best Regards,

PurCell Bio, Inc.

Healey-Driscoll Administration Invests $800K for Biomanufacturing in Southeastern Massachusetts.

Grant to Mansfield Bio-Incubator Will Accelerate Cell and Gene Therapy Development, Expand Workforce Development in an Underserved Region of the State

February 14, 2024

Source: Innovation Institute at MassTech

WESTBOROUGH, Mass. – Today, the Healey-Driscoll Administration announced $800,000 to bolster the biomanufacturing sector in Southeastern Massachusetts through a new grant to the Mansfield Bio-Incubator, a regional biotech and life sciences incubator that assists local entrepreneurs and startups to accelerate their projects, attract new talent, provide training, and boost capital investment.

The new, two-year grant from the Technology & Innovation Ecosystem Award grant program, managed by the Innovation Institute at the Mass Tech Collaborative, will help Mansfield Bio-Incubator support growing companies working to innovate in cell and gene therapy, and 3D culture technology. The capital investment will allow the facility to purchase new equipment to boost biomanufacturing in the region, helping respond to increased demand from the Bio-Incubator's existing members and to scale-up support for new entrepreneurs in Southeastern Massachusetts. In turn, this will drive increased economic growth and boost workforce training activities in an underserved region with a diverse population.

“Biomanufacturing has the potential to make Massachusetts more sustainable while at the same time meeting our production needs, workforce demands and business development goals,” said Governor Healey. “It has an important role to play in our national defense and drug manufacturing, and in securing the health and safety of our residents. We want to congratulate the Mansfield Bio-Incubator for their hard work to address these priorities by leveraging the incredible talent of Southeastern Massachusetts and helping us lead the nation in this emerging sector.”

“Communities across the state should have access to the resources needed to become the future centers of biotech, biomanufacturing, and life sciences,” said Lieutenant Governor Kim Driscoll. “This strategic grant to the Mansfield Bio-Incubator will draw investments, small businesses, and new workforce opportunities to grow the sector in the region. As a result, we can build more a more dynamic ecosystem and increase the innovative potential for companies in the Southeast.”

“By boosting this growing regional biomanufacturing hub, the state is investing in R&D technologies that will foster the growth of more innovative companies advancing human health within the state,” said Secretary Yvonne Hao of the Executive Office of Economic Development. “Through this grant, we can ensure that biomanufacturing firms specializing in regenerative medicine, biomedical engineering, and cell therapy can expand their production to meet demand, discover new breakthroughs, and maintain international competitiveness.”

Mansfield Bio-Incubator is supported by two principal partners on the project, Wheaton College in Norton, who will help develop experiential learning opportunities for students and The Capital Network in Cambridge, who will help improve access to venture funding. The incubator will drive economic growth and increase competition in biomanufacturing, allowing the Mansfield Bio-Incubator to accelerate the maturation of a cell and gene therapy and 3D culture hub in Southeastern Massachusetts.

“Given this sector’s novel approach to assembling the elements that drive our economy, we are proud to support the Mansfield Bio-Incubator, this world-class cluster, and the economic competitiveness of Southeastern Massachusetts,” said Pat Larkin, Director of the Innovation Institute at MassTech. “We congratulate the Bio-Incubator on their efforts to grow startups, workforce development opportunities, and the necessary scaffolding to grow biomanufacturing across this region.”

“The role of life sciences in both the well-being of humanity as a whole and the economic development will only increase in the coming years,” said Alexander Margulis, Chief Operating Officer of Mansfield Bio-Incubator. “With Massachusetts being at the forefront of groundbreaking scientific discoveries, more mini clusters across the state will cement the Commonwealth’s lofty status as a life science mecca. The partnerships, such as one between MassTech Collaborative and Mansfield Bio-Incubator, are critical for implementing this vision.”

At the national level, the Biden-Harris administration has targeted biomanufacturing for expanded development and has recommended making an increased investment in the field, given its importance to increased drug development, expanded supply chains, and national security.

“The work that the Mansfield Bio-Incubator is doing to increase the scope and quality of experiential learning opportunities for college students such as Allison Darling of North Attleboro, who has trained at Phenomenex and EverCell Bio, exemplifies the best of industry-academia collaboration, and will help to ensure the development of Southeastern Massachusetts as an up-and-coming player in the biomanufacturing and life sciences sectors,” said Imran Chowdhury, a member of the Mansfield Bio-Incubator’s Advisory Board and Dean of the Ketner School of Business at Catawba College in North Carolina. 

The Mansfield Bio-Incubator estimates that it will take four years to incubate 15 new companies, which will create 30 jobs and lead to the training of 50 interns to boost the talent pool for biomanufacturing. The facility also anticipates that increased momentum around biomanufacturing in Southeastern Massachusetts could lead to larger companies moving to the area to expand the sector. These funds will also enable them to support future industrial biomanufacturing cluster development and continued support of the diverse population they serve, including 10 female founders and a fledgling femtech cluster comprised focused on women’s health products or services.

"Bio-incubators, such as the Mansfield Bio-Incubator, are instrumental in the success of Massachusetts' larger life sciences sector by serving as a regional hub for world-class innovation and growth through the creation of well-paying, skilled jobs that strengthen the Commonwealth's competitive edge in the marketplace,” said Senator Paul Feeney (D-Foxborough). “I am thrilled with the announcement of an additional $800,000 in funding to the Mansfield Bio-Incubator to continue bringing new ideas to the market that have the potential to make lives better and fuel the region's flourishing biotech and life sciences industries. Massachusetts is a world leader in this sector, and with the incredible work being done at the Mansfield Bio-Incubator, we are showing that our region can be a hub for innovators. I commend the Mansfield Bio-Incubator for serving as an example of excellence for all Massachusetts bio-incubators, and I thank the Healey-Driscoll Administration and the MassTech Collaborative for recognizing and investing in this tremendous local asset.”

“Massachusetts is #1 in many things, therefore it is paramount that we be #1 in workforce development,” said Representative Adam Scanlon of the 14th Bristol District. “I’m excited to hear that this grant will help leverage opportunities to create jobs for all people in our region within the STEM field. We must continue to support organizations like Mansfield Bio so that we can set the example as the state with the fastest growing and most diverse workforce. Our local businesses are what embodies the fabric of innovation in Massachusetts.”

“I am so proud of the continued success of Mansfield Bio and the local partnership with Wheaton College, a win-win,” said Representative Jay Barrows of the 1st Bristol district, who represents the town of Mansfield.

“We are thrilled that the support needed to grow and accelerate cell and gene therapy has been awarded to Mansfield Bio-Incubator in order to further their great work."  said Kevin Dumas, Town Manager of Mansfield. "It is the collaboration with our partners in government along with other public and private sectors that make life sciences in Massachusetts thrive.  Mansfield remains committed to growing this important sector in the Southeast Region of the State and is glad to get behind and support this important initiative.”

The Tech and Innovation Ecosystem grant program seeks to strengthen the technology and innovation ecosystem in regions across the Commonwealth through support for projects or initiatives that contribute to a competitive advantage for existing and emerging industry clusters across Massachusetts. The program aims to improve conditions overall for job growth, drive business expansion and new business formation, and impact other indicators of growth in the innovation economy such as capital formation, increased export products and services, improved labor pools, and increased wages.

To date, the program has invested nearly $12 million in six projects located across the state, focused on diverse sectors such as autonomous vehicles, blockchain, blue tech, fintech, and robotics.

###

About the Innovation Institute at the Massachusetts Technology Collaborative

The MassTech Collaborative is a quasi-public economic development agency that strengthens the competitiveness of the tech and innovation economy by driving strategic investments, partnerships, and insights that harness the talent of Massachusetts.  The Innovation Institute is the division of MassTech that advances its core mission of innovation and cluster growth across the Commonwealth.  Created in 2003, the Innovation Institute intervenes in the economy in the following four ways:

  • Conducts research and analysis that improves the state’s understandings of unmet needs and opportunities in the innovation economy;

  • Serves as convener and key strategic broker on the landscape;

  • Manages high-value projects on behalf of the Commonwealth; and

  • Makes strategic investments in support of innovation-based economic development.

For more information, visit https://innovation.masstech.org/.  

Mansfield Bio-Incubator Expanded The Leadership Team

MANSFIELD (MA) To expand Mansfield BioIncubator role as ecosystem hub supporting the development of the biotech industry in Southeastern Massachusetts, Mansfield Bio-Incubator added two pharma veterans to the team. Julia Rashba-Step, PhD and Alex Shlyankevich, PhD will serve as a Mentorship Director and Investment Relations Director respectively.

Dr. Julia Rashba-Step is a senior pharmaceutical professional with an extensive background in nanotechnology, biotechnology and pharmaceutical industries. Julia has experience working at both small companies (Epic Therapeutics) and global pharmaceutical companies including Baxter, Wyeth and Pfizer, where she held positions of growing responsibilities, leading formulation, packaging and delivery groups Julia's most recent position was a Vice President of Research & Development and Alliance Management at Phosphorex where she worked closely with Pharma and Biotech partners to help advance cutting edge innovative technologies into the critical pre-clinical and clinical stage programs. Dr Rashba-Step has multiple scientific publications in the field, as well as patents and and serves on multiple Advisory Boards. Julia is passionate about mentoring and coaching as the way of giving back to the community. Julia was a Co-chair of Women’s leadership Network at Pfizer, served as a Mentor for HBA (Healthcare Business Women’s association. Julia received a Life coach certification with the focus on career development coaching. Julia served as a mentor for MassBio Connect program, helping biotech startups to develop their business cases.

Over the course of his 25-year career in the pharmaceutical industry, Dr. Alex Shlyankevich has contributed to numerous drug discovery, development and commercialization programs in technical and leadership roles. As Director of mRNA Preclinical Testing at Moderna, he established and led a department responsible for evaluating mRNA therapeutic and vaccine candidates during the company’s formative period. In his role as Senior Director of Analytical R&D at Nitto-Denco, Alex managed contract services for the global oligonucleotide-based therapeutics industry. Building on his industry expertise, Alex has dedicated the last 9 years to creating and managing a life science investment portfolio for the VC arm of an international family office, resulting in a number of exits via acquisitions and IPOs. Dr. Shlyankevich currently serves on the board of four therapeutic and medical device companies. Alex holds an MS and PhD from the First Moscow State Medical University.

“We are thrilled to welcome Julia and Alex to our leadership team. Their expertise and dedication will help us achieve our goal of providing superior mentoring to startups and creating new companies," said Dr. Russ Yukhananov, President of Mansfield Bio-Incubator, "We look forward to working with Julia and Alex to build a world-class life sciences ecosystem in the region.”

Mansfield Bio-Incubator is currently accepting applications for the Spring 2024 Mentoring Program cohort and for the $20K Pitching Competition Challenge on May 21, at no cost to the startup company.

The Mentoring Program is a 6-week program tailored to a given company’s individual needs, with the end goal to create a compelling pitch deck. The company then has a chance to practice pitching in front of the key stakeholders, with the initial $20K Challenge taking place on May 21, 2024.

Apply here.

3Daughters Successfully Closes Over $2 million in First Tranche of Seed Financing Round

Funding will accelerate development of a Novel IUD for contraception for IND filing in 2024

January 22, 2024 08:00 ET| Source: 3Daughters

MANSFIELD, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- 3Daughters, a clinical development company fueling evolutionary healthcare for women, announces closing of the first tranche in excess of $2 million in a Seed Round. This round was led by Thairm Bio, with a group of life science investors, and joined by the Argosy Foundation, Wexford Science and Technology, LLC, UMass Amherst, and other undisclosed investors. The financing signifies a pivotal milestone in the company’s mission to innovate for women with the development of a game-changing IUD (intrauterine device) for contraception to address insertion pain, a major barrier to adoption.

3Daughters has a unique and frameless delivery platform, based on physics and geometry, for targeted therapy directly into the uterus. 3D-001, a novel IUD containing copper, a proven spermicide for contraception, is the first product resulting from the technology. Combined with a novel and patented i-Slider™ for insertion and r-Slider™, a simple magnetic retriever, 3Daughters will be eliminating a number of pain points that keep women from getting one of the most effective forms of birth control. Proceeds from the funding will be used to advance the Company’s lead IUD asset, 3D-001, through an IND filing followed by a Phase 1 clinical trial this year.

Mary Beth Cicero, Co-Founder and CEO of 3Daughters, commented, “We are thrilled to have garnered such strong support from our existing and new investors, all of whom share our vision of solving health issues for women. This investment marks the next chapter for 3Daughters and allows us to execute our streamlined development plans to move into the clinic. With this funding, we are getting closer to our promise to address significant and neglected issues, like IUD insertion pain, that women have been putting up with for over 50 years.”

“The lack of innovation in women’s health and the significant need 3Daughters is addressing drew me to this investment. It is clear that women’s health gets overlooked from an investment perspective and I want to be a part in changing that dynamic,” commented Mark Bamforth, Thairm Bio. “Given the apparent urgency for new and effective contraceptive options and the pain women experience with IUDs, I recognized the need and formed an investment vehicle with my colleagues to help fund this important innovation for women.”

Emily Van Dunk, Executive Director of the Argosy Foundation, stated, “Supporting 3Daughters aligns with our vision of empowering people and making a positive impact on communities globally. The recent changes in reproductive rights have strengthened our resolve to continue funding access to contraceptives, and we continue to support advancing women’s health with our investment in 3Daughters. We believe in the transformative potential of the 3Daughters novel IUD to make a significant impact for women.” The Argosy Foundation is a private family foundation founded in 1997 by John Abele, Founding Chairman of Boston Scientific.

“Wexford SciTech Fund is focused on investing in early seed opportunities in life sciences. We were attracted by the innovative technology of a frameless uterine delivery platform and the significant market need of addressing IUD insertion pain,” commented Thomas Osha, Executive Vice President, Wexford Science & Technology, LLC. “3Daughters has an outstanding Scientific Advisory Board and through this partnership, we will provide access to Wexford’s substantial network of university talent, industry experts, and strategic partners, as well as resources to help them scale and grow even faster. The 3Daughters team’s commitment to innovation for women, solid operational, scientific, and executive leadership, and, most importantly, the potential for positive impact on women’s health make this investment an exciting venture for us.”

“We aim to bring in an additional $1M to close the planned $3M seed financing round by the first quarter of 2024,” stated Mary Beth Cicero, Co-Founder and CEO of 3Daughters, and Shelley Amster, Co-Founder and Chief Strategy & Growth Officer.

About 3Daughters™

3Daughters is a clinical development company focused on evolutionary healthcare for women where attention is desperately needed for cutting-edge research and innovation. The Company’s first product, (3D-001), is a frameless, magnetic, nonhormonal intrauterine device (IUD) for long-acting contraception that conforms to a woman’s body and is combined with our unique, patented Slider™ system (insertion/ retrieval) designed for easy and less painful insertion and retrieval. 3Daughters’ vision is to solve health issues for women, particularly significant (neglected) problems. 3Daughters plans to radically transform the IUD market by eliminating the major adoption barrier — insertion pain. This pain is associated with all current rigid, plastic T-shape framed IUDs on the market and prevents women from selecting one of the most effective forms of birth control. Visit 3daughtershealth.com for more information.

Contact:

Mary Beth Cicero
info@3Daughtershealth.com

Mansfield Bio-Incubator Receives $1.25M Build-to-Scale (B2S) Grant from Economic Development Administration (EDA) to Help Establish Southeastern Massachusetts Life Science Ecosystem.

Mansfield Bio-Incubator is proud to announce a $1.25M Build-to Scale (B2S) award from EDA. This EDA investment will help establish the Southeastern Massachusetts Life Science Ecosystem, a regional biotech ecosystem that fosters growth within existing biotech firms, attracts new biotech firms, and supports the industry cluster through a prepared and skilled workforce. To foster an ecosystem that supports the development of the biotech industry in Southeastern Massachusetts, the Incubator will take on activities to scale existing, proven mentorship programs that support workforce development and entrepreneurship. The Southeastern Massachusetts Life Science Ecosystem will tap into existing resources including data, angel and venture capital investors, existing partners in biotech and professional trade organizations to attract additional startups, investors, and higher education institutions located in and near four Gateway Cities, and existing partners in biotech and professional trade organizations to attract additional partnerships. This initiative seeks to support at least 80 new biotech startups, assist in securing over $200 million in venture money, and facilitate 10 strategic partnerships, encouraging collaboration and mutual growth within the sector.

Can New Biotech Innovation Prevent Type 2 Diabetes Epidemic in Advance?

Key Takeaways:

  • Stapgen is a start-up biotech company based in Boston, focused on thwarting the Type 2 diabetes pandemic.

  • Stapgen produces the STAP-test, a patented medical test kit that measures Intestinal Alkaline Phosphatase (IAP) to detect intestinal IAP deficiency (IAPD) and early symptoms of Type 2 diabetes.

  • With their IAP-panel, the risk level of developing Type 2 diabetes can be estimated far in advance, potentially aiding in disease prevention.

As countless people worldwide battle the incessant rise of Type 2 Diabetes, one groundbreaking start-up seems poised to turn the tide. Introducing Stapgen – a Boston-based biotech firm that’s making strides in potentially curtailing the Type 2 Diabetes epidemic. Established by Biplap Malo, Stapgen is tackling this global health crisis by confronting the precursor stages of diabetes.

Utilizing innovative technology and medical test kits, they’ve managed to identify key risk indicators for the condition in advance. Their core product, the STAP-test, has the ability to indicate potential health risks before the onset of life-threatening symptoms – a major game changer in the field of preventive medicine.

Stapgen’s offering is unique – and necessary. The STAP-test is a de novo patented method that measures Intestinal Alkaline Phosphatase (IAP) levels, a critical indicator for Intestinal Alkaline Phosphatase Deficiency (IAPD) and incipient Type 2 Diabetes. Thus, it addresses a previously unmet need in the healthcare field, allowing healthcare professionals and patients alike to take preventive steps against the disease.

But that’s not all. Stapgen’s main differentiator lies in its IAP-panel, which can forecast the risk level of developing Type 2 Diabetes in advance. By intercepting the pathogenesis in the lag phase between IAPD to full symptomatic Type 2 Diabetes, the possibility of preventing the disease entirely becomes significantly more plausible.

Within such a dynamic industry, the future for Stapgen looks positive. Their innovative approach could deter the increasing spread of diabetes, serving as a beacon of hope for all susceptible individuals. The potential to prevent rather than just manage the disease presents a remarkable leap for not just the biotech sphere, but the healthcare industry as a whole.

In an age where thousands grapple with the reality of Type 2 diabetes, companies like Stapgen who offer hope for the future, deserve the recognition. The journey of Stapgen can be followed on their website, as well as on other social platforms such as Twitter, Facebook, and LinkedIn.

Aclarity Secures $16M in Series A Funding to Deploy Low Energy PFAS “Forever Chemical” Destruction Solution

Mansfield, MA, November 2, 2023 – Aclarity, Inc., the leader in PFAS (Per- and Polyfluoroalkyl Substances) “forever chemical” destruction, announced today the successful completion of its Series A funding round, raising $15.9 million. This funding round was led by Aqualateral, with participation from the HG Ventures, Bidra Innovation Ventures, Nor’easter Ventures, MassVentures, and Burnt Island Ventures. This latest round of funding builds upon a $3.3 million Seed round secured in 2022, propelling the company into an exciting new phase of commercial expansion and innovation.

PFAS, often referred to as “forever chemicals” due to their persistent nature in the environment, have become a major concern worldwide due to their detrimental impact on ecosystems and human health. Aclarity’s Octa™ system offers a sustainable solution for the complete eradication of PFAS contaminants, heralding a new era in wastewater treatment and environmental remediation for landfills, water and wastewater treatment plants, and industrial facilities – where PFAS is particularly prevalent.

Over the last year, Aclarity has deployed mobile systems with full-scale reactors across the country to destroy PFAS chemicals continuously. This has allowed the team to successfully treat PFAS in waters ranging from low ng/Ls in tap water, all the way to landfill leachate treated by foam fractionation with PFAS concentrations of milligrams per liter, including short-chain compounds like PFBS and demonstrating real time PFAS destruction in the field. Aclarity’s achievements have garnered the attention of groups such as Frost & Sullivan, who awarded Aclarity their Company of the Year Best Practices award for 2023 in the North American PFAS treatment industry. With the support of this investment, Aclarity has broadened its pipeline across several industries requiring PFAS destruction such as the waste industry as well as food and beverage manufacturing and the pulp and paper industry. The Series A funds will play a pivotal role in scaling up manufacturing and supply chain capabilities, further increasing market penetration, and advancing partnerships to address PFAS contamination challenges on a global scale.

“The industry is overwhelmingly demanding a solution to the PFAS problem, responding to existing and pending regulations. We are extremely grateful for the enthusiastic support from our investors and the confidence they have shown in our mission to combat the widespread issue of PFAS contamination,” said Julie Bliss Mullen, Founder and CEO of Aclarity. “The Series A funding is already enabling us to grow our team, build more PFAS destruction skids and bring them to more communities and industries, ultimately making a lasting positive impact on public health and the environment.”

Aclarity’s innovative approach to PFAS destruction has garnered attention and support from both investors and environmental advocates alike. The technology boasts several key advantages, including its cost-effectiveness, environmental safety, and efficiency in eliminating PFAS compounds, offering a sustainable alternative to conventional remediation methods.

“Aclarity has the potential to revolutionize the field of environmental remediation and solve one of the most pressing environmental challenges of our time. We are confident that they will deliver on this promise,” said Jiten Manglani, Aqualateral’s Chief Investment Officer. “The Aclarity team has the capacity and vision to deliver far-reaching transformative results to communities across the globe.”As Aclarity continues to make strides in the fight against PFAS pollution, the company remains committed to its core mission of destroying PFAS to safeguard the environment and public health. The Series A funding will be instrumental in driving Aclarity’s growth and accelerating the deployment of its groundbreaking technology to communities and industries in need.

For more information about Aclarity and its PFAS destruction technology, please visit

www.aclaritywater.com

 

About Aclarity Inc.

Aclarity is revolutionizing the elimination of persistent and hazardous “forever chemicals” known as PFAS, which accumulate in human and animal tissues and persist indefinitely in our environment. Aclarity’s Octa™ PFAS destruction systems employ innovative proprietary technology to disrupt the ongoing PFAS contamination cycle. The conventional approach for removing and disposing of PFAS has led to concentrated PFAS materials being reintroduced into the environment through methods like landfill disposal, incineration, and deep well disposal, recontaminating the air, soil, and water. PFAS compounds are inherently resilient due to their strong molecular bonds. Until now, the prevailing method of “remediating” PFAS has involved a perilous cycle of extraction and disposal, either by returning the extracted PFAS to landfills or by incinerating it and emitting toxic aerosols into the atmosphere. Aclarity’s technology employs electricity to sever the carbon and fluorine bonds that give PFAS compounds their durability, thus putting an end to the perpetual PFAS contamination cycle.

 

Media Contact:

Leanne Hersey

Vice President of Marketing, Aclarity

leanne.hersey@aclaritywater.com

Unsmudgeable Joins Mansfield Bio-Incubator Aiming to Revolutionize the Eye Care.

Those of us who wear glasses routinely struggle with keeping the eyewear clean thereby exerting additional strain on eyes which in turn affects quality of life and could worsen the eyesight. Unsmudgeable, our newest member company, is working on addressing this challenge.

Unsmudgeable is revolutionizing eyewear with the first permanent smudge-free lens coating. While current lens coatings cause oil from fingers to cluster on the lens surface, Unsmudgeable's innovative formula allows oil to spread evenly without obstructing vision. This creates a crystal clear viewing experience without the need for constant cleaning and lens wipes. Unsmudgeable's coating is also free of harmful PFAS chemicals found in many optical coatings today. Their non-toxic formula is safe for the environment and skin, while still providing durability and scratch resistance. As Unsmudgeable scales up production, this revolutionary coating will be applied during mass manufacturing of safety and prescription eyewear. By optimizing lens coatings for the first time, Unsmudgeable brings groundbreaking innovation that will change how we see and experience eyewear. The days of smudged and blurry vision are over thanks to Unsmudgeable's new technology.

In short time Unsmudgeable has been our member, the team made significant progress in advancing the research. "Mansfield Bio-Incubator's team has been extremely supportive in our work. They went extra mile to make sure that we are able to push our project ahead. Without their help, we would not have been able to advance our work as far as we did", said Swarnambika Shiv, Founder and CEO. 

Unsmudgeable is currently generating data to prepare for fundraising. The company is looking for a lead investor for the seed round. For more information, visit the website https://www.unsmudgeable.com or contact swarnambikashiv@unsmudgeable.com.

3Daughters™ Emerges as a Transformative Women’s Healthcare Company and Announces Key Leadership and Scientific Advisory Board Appointments

July 13, 2023 08:00 ET| Source: 3Daughters


3Daughters aims to uniquely address and fill major gaps in Women’s Health

Assembles experienced Women’s Health team and World Class SAB to advance development of novel long-acting reversible contraception technology

MANSFIELD, Mass., July 13, 2023 (GLOBE NEWSWIRE) --  3Daughters, an emerging clinical development company fueling evolutionary healthcare for women, announces key senior leadership appointments and the formation of a Scientific Advisory Board (SAB) to support the development of its lead asset (3D-001), a highly innovative and frameless intrauterine device (IUD) for contraception.

Women’s Health and associated research remains highly underserved but represents a significant market opportunity for improved treatment options for women around the globe. 3Daughters’ mission is to usher in a new era of refined and innovative Women’s Health products starting with an elegantly designed self-assembling IUD technology. With a unique frameless uterine delivery platform, 3Daughters expects to transform the rapidly growing IUD market in the US and address the need for improved contraceptive options and potentially lower the number of unintended pregnancies.

Research shows that IUDs are one of the most effective forms of contraception and tend to be women’s preferred choice. However, IUD insertion pain is common, and many women describe it as ‘severe to excruciating’. The current T-shaped framed IUDs (five approved in the US) have arms and dangling strings needed for removal and this outdated design has not changed significantly since first entering the US market in 1988.

3Daughters has addressed IUD insertion pain with a frameless self-assembling technology that is expected to be easily inserted into the uterus with a uniquely designed i-Glider™ for insertion and a simple magnetic retriever (r-Glider™) completes the process for removal. Both the IUD technology and Glider (inserter/retriever) system are patented. This sophisticated solution will overcome the major barrier to IUD adoption and take away the ‘fear factor’ for practitioners and patients relating to IUD insertion pain.

3Daughters has assembled a highly experienced Women’s Health team to drive the development plan forward for its lead product candidate, 3D-001, to enter the clinic next year. These key leadership roles and appointments are:

Dr. Gary Shangold named Chief Medical Officer (CMO) – Brings over three decades of medical, scientific and executive experience as a reproductive endocrinologist. He has held roles as CMO of Enteris BioPharma and Xanodyne Pharmaceuticals, and CEO of NovaDel Pharma. Dr. Shangold previously held senior roles in clinical research and regulatory affairs at RW Johnson Pharmaceutical R&D (J&J) and as Medical Director for Ob/Gyn/Infertility at Serono Labs.

Dr. Mary Mahony named Chief Scientific Advisor (CSA) – Seasoned medical affairs veteran with almost four decades of experience in reproductive medicine and endocrinology. Most recently, she was EMD Serono’s Vice President of Fertility and Endocrinology leading the medical team for pharmaceutical products and IVF laboratory medical devices. Her research focus includes human sperm pre-fertilization capacitation events on the cellular level, and she has extensive publication and journal credits in this field.

Dr. William Bracken named Head of Toxicology – Brings extensive toxicology and preclinical experience regarding drug safety having held senior roles at AbbVie as Director of Global Preclinical Safety and Chair of the Drug Safety Committee. Dr. Bracken also conducted expansive research at Oak Ridge National Labs, Fred Hutchinson Cancer Research Center and the Midwest Research Institute focused on mechanisms of carcinogenicity.

In addition, the Company has engaged a group of eight Key Opinion Leaders (KOLs) in Women’s Health as members of its Scientific Advisory Board:

David F. Archer, MD, Chair, 3Daughters, Scientific Advisory Board
Professor of Obstetrics and Gynecology & Director of the Clinical Research Center, Eastern Virginia Medical School

Chanelle Coble-Sadaphal, MD
Chief, Division of Adolescent Medicine, NYU Grossman School of Medicine

Tara Kumaraswami, MD, MPH
Associate Professor of Obstetrics and Gynecology
Associate Director, Ob/Gyn Residency Program
UMASS Chan Medical School

Siripanth Nippita, MD, MS
Chief, Division of Family Planning and Clinical Associate Professor, NYU Grossman School of Medicine

Mary Lake Polan, MD, PhD, MPH
Professor of Clinical Obstetrics, Gynecology, Reproductive Sciences, Yale University School of Medicine

David Turok, MD, MPH, FACOG
Chief, Division of Family Planning & Associate Professor, Department of Obstetrics and Gynecology, University of Utah

James A. Simon, MD, CCD, NCMP, IF, FACOG
Past President, The International Society for the Study of Women’s Sexual Health (ISSWSH)
Clinical Professor of Obstetrics and Gynecology, George Washington University

Carolyn Westhoff, MD
Professor of Obstetrics and Gynecology, Reproductive Health, Population, Family Health, and Epidemiology, Columbia University
Editor, Contraception

Mary Beth Cicero, Co-Founder and CEO of 3Daughters, commented, “The 3Daughters story is rapidly progressing with our new highly-experienced Senior Leadership team. It is my privilege to work alongside Drs. Shangold, Mahony and Bracken who will bring their collective Women’s Health expertise to every aspect of our clinical development program and rapidly advance our product candidate through regulatory approval. Like me and my Co-Founder, Shelley Amster, they are determined to bring more innovation to Women’s Health and address problems like IUD insertion pain that has been difficult to solve and neglected.”

“Also, we are extremely pleased to have the support and advice of a World-Class group of scientific thought leaders and clinicians as members of our Scientific Advisory Board who will help provide advice and guidance for our research and development efforts.”

Ms. Cicero added, “As we prepare to file our IND and complete our Phase 1 study next year, I am looking forward to the 3Daughters team delivering on our planned milestones. We are dedicated to Women’s Health and doing everything we can to bring innovation to this field, starting with our proprietary frameless IUD and Glider delivery system.”

Shelley Amster, Co-Founder and Chief Strategy and Growth Officer of 3Daughters stated “Women make up more than 50% of the global population, which means the target market for products focusing on their health is massive. Supporting innovation in female health doesn’t just benefit women, it helps everyone. Our primary mission at 3Daughters is to champion women and drive innovation and superior products that promote their health.”

Background on the 3Daughters Uterine Delivery Platform and IUD Solution

Invented at University of Massachusetts, Amherst by Dr. Carlos Gradil, a world renowned veterinary reproductive specialist, the 3Daughters frameless IUD is ‘simple, smart, and sophisticated’ based on physics and geometry. The patented magnetic technology self – assembles in the uterus into a stable triangular ‘ring’ conformation that adapts to the uterine environment. Dr. Gradil demonstrated the safety and contraceptive effectiveness of the self-assembling IUD technology in performance horses and this data has been published in peer-reviewed journals.

For more information on this trailblazing technology, visit the 3Daughters website: 3daughtershealth.com.

About 3DaughtersTM

3Daughters is an emerging company focused on evolutionary healthcare for women where attention is desperately needed with cutting-edge research and innovation. The Company is developing its lead product (3D-001), a frameless, magnetic, nonhormonal intrauterine device (IUD) for long-acting contraception, with a goal of radically transforming the IUD market by eliminating the major adoption barrier — insertion pain. This pain is associated with all current T-shape framed IUDs on the market and prevents women from selecting one of the most effective forms of birth control. Visit 3daughtershealth.com for more information.

Contact
Mary Beth Cicero
info@3daughtershealth.com

Original Source: https://www.globenewswire.com/news-release/2023/07/13/2704296/0/en/3Daughters-Emerges-as-a-Transformative-Women-s-Healthcare-Company-and-Announces-Key-Leadership-and-Scientific-Advisory-Board-Appointments.html

Neuronity Therapeutics Secures $780k Grant from The Michael J. Fox Foundation for Parkinson's Research

By: Neuronity Therapeutics, Inc.

BOSTON - July 3, 2023 - PRLog -- Neuronity Therapeutics, Inc., a pioneering biotech company focused on neurodegenerative diseases, is delighted to announce the receipt of a $780k grant in collaboration with the University of Georgia (UGA) from The Michael J. Fox Foundation (MJFF). As the largest nonprofit foundation for Parkinson's disease, MJFF's Therapeutics Pipeline Program (TPP) aims to accelerate the development of therapeutic pipelines in partnership with academia and industry.

Neuronity has forged a collaboration with Dr. Jae-Kyung Lee, Associate Professor of Physiology and Pharmacology, at UGA to advance a research program aimed at restoring homeostasis of microglia, the residential immune cells in the brain affected by Parkinson's disease. This groundbreaking 18-month project will support Neuronity and UGA in validating a clinically applicable gene therapy utilizing Adeno-Associated Virus to upregulate target molecules in microglia. The innovative gene therapy holds a substantial potential to modify disease outcomes for Parkinson's disease patients.

"The grant from MJFF is a significant milestone for Neuronity in our therapeutic development journey, as well as an acknowledgment of the support from the esteemed shareholders in MJFF's community," expressed Hyun Joon Lee, PhD, Founder and CEO of Neuronity. "We are thrilled to have the opportunity to engage with these shareholders and collaborate with MJFF's staff for our upcoming fundraising efforts. The collaboration with Dr. Jae-Kyung Lee will ensure that we maintain a high standard of scientific research while progressing towards the clinical development of this therapy."

Through this grant, Neuronity will not only receive vital financial support but will also gain access to MJFF's extensive network of researchers and advisors, both within their community and among external partners. This invaluable network will provide valuable guidance and foster collaboration, further propelling Neuronity's mission to develop effective treatments for Parkinson's disease.

Neuronity is committed to making a positive impact on the lives of Parkinson's disease patients, and this grant from MJFF reaffirms their dedication to advancing innovative therapies. The company looks forward to the next phase of their research and development journey, working closely with MJFF, UGA, and their shareholders to bring about meaningful change in the field of neurodegenerative diseases.

About Neuronity Therapeutics, Inc.: Neuronity is a biotech company dedicated to revolutionizing the treatment of neurodegenerative diseases. With a focus on age-related neurological disorders, such as Parkinson's disease, our cutting-edge gene and cell therapy programs aim to restore healthy immune cell function in aging brains. By targeting the root causes of these conditions, we strive to reduce the unmet needs of patients, families, and caregivers. Our mission is to improve the quality of life for individuals affected by neurodegenerative diseases through groundbreaking interventions and strategic collaborations. Neuronity accomplished the prestigious Fall 2022 Science Inc.™ Accelerator Program, hosted by the Innovation Space in Delaware and formed a team of exceptional scientists and enlisted the support of seasoned advisors. For more information, visit: www.neuronitytx.com or find us on LinkedIn at Neuronity Therapeutics, Inc.

Contact
Hyun Joon Lee, PhD
CEO
***@neuronitytx.com